Online inquiry

IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9927MR)

This product GTTS-WQ9927MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EPHA3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005233.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2042
UniProt ID P29320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9927MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3895MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ1171MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ5489MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ10798MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ9898MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ9373MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ3298MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ7937MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW